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Prognostic Impact of Mechanical Activation Delay by Cross Correlation Analysis in Heart 1 
Failure Patients with narrow QRS treated with Cardiac Resynchronization Therapy: an 2 
Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT) Trial Sub-3 
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Abstract 51 
 52 
Background: Cross Correlation Analysis (CCA) using tissue Doppler imaging (TDI) shown to 53 
be associated with outcome after cardiac resynchronization therapy (CRT) in heart failure (HF) 54 
patients with wide QRS. However, its significance in narrow QRS patients treated with CRT is 55 
unknown.  56 
Objectives: The aim of the current study was to investigate the association of mechanical 57 
activation delay by CCA with study outcome in HF patients enrolled in the EchoCRT trial. 58 
Methods: Baseline CCA could be performed from TDI in the apical views in 807 of 809 59 
(99.7%) enrolled patients while 6-months follow-up could be performed in 610 of 635 (96%) 60 
patients with available echocardiograms. Patients with a pre-specified maximal activation delay 61 
≥ 35 ms were considered to have significant delay. The study outcome was HF hospitalization or 62 
death. 63 
Results: Out of 807, 375 (46%) patients did not have delayed mechanical activation at baseline 64 
by CCA. Patients without delayed mechanical activation randomized to CRT-On had an 65 
increased risk of poor outcome (HR 1.70, 95% CI 1.13-2.55, P=0.01) in comparison to those 66 
with CRT-Off with a significant interaction term (P=0.04) between delayed mechanical 67 
activation and device randomization for the endpoint. Among patients with paired baseline and 68 
follow-up data with no events before 6-months follow-up (n=541), new-onset delayed 69 
mechanical activation in the CRT-On group showed significant increase in unfavorable events 70 
(HR 3.73, 95% CI 1.15-12.14, P=0.03). 71 
Conclusions: In the EchoCRT population, absence of delayed mechanical activation by CCA 72 
was significantly associated with poor outcomes possibly due to the onset of new delayed 73 
mechanical activation with CRT pacing. (Echocardiography Guided Cardiac Resynchronization 74 
Therapy [EchoCRT] Trial; NCT00683696) 75 
Key words: heart failure, cardiac resynchronization therapy, echocardiography, dyssynchrony, 76 
tissue Doppler imaging. 77 
Condensed Abstract 78 
In the current study we applied cross correlation analysis method (CCA) to assess mechanical 79 
activation delay in the population of echocardiography guided cardiac resynchronization therapy 80 
(EchoCRT) trial in which CRT was implanted in patients with narrow QRS (<130ms). CRT was 81 
fatal to patients with no activation delay at baseline which was possibly due to the pacemaker 82 
induced new activation delay.  83 
Abbreviation List 84 
CRT = cardiac resynchronization therapy 85 
ECG = electrocardiographic 86 
HF = heart failure  87 
LVEF = left ventricular ejection fraction 88 
TDI = tissue Doppler imaging 89 
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Several studies in the past have demonstrated that the assessment of mechanical 90 
dyssynchrony by echocardiography can supplement current electrocardiographic (ECG) criteria 91 
(wide QRS ≥ 120 ms) in selection of CRT candidates leading to an overall reduction in the non-92 
responders rate.(1-3) However, conventional methods of identifying dyssynchrony based on 93 
segmental time-to-peak measurements have failed when applied in randomized trials for 94 
selecting patients for CRT with narrow QRS (<130ms).(4,5) 95 
The largest CRT trial conducted on narrow QRS (<130 ms) patients - echocardiography 96 
guided cardiac resynchronization therapy (EchoCRT) - demonstrated that HF patients with 97 
narrow QRS (<130 ms) do not respond to CRT despite the presence of baseline mechanical 98 
dyssynchrony by time-to-peak methods by either tissue Doppler longitudinal velocity or speckle 99 
tracking radial strain.(4) In fact, an increased incidence of mortality was observed in patients 100 
randomized to CRT-On in comparison to the control group and the trial was stopped due to 101 
futility without achieving its complete target population. Another trial - The Resynchronization 102 
therapy in narrow QRS (RethinQ) - performed before EchoCRT with similar design where 103 
mechanical dyssynchrony was one of the selection criteria, also showed no benefit of CRT in HF 104 
patients with narrow QRS.(5)    105 
More recently, it was shown that peak-to-peak measures of mechanical dyssynchrony 106 
may be influenced by contractile heterogeneity or scar not responsive to CRT.(6) Patterns of 107 
myocardial mechanics that have been shown to reflect electrical delay have shown very 108 
promising results and seem to better identify a true substrate for CRT response.(6-8) These 109 
newer methods seem superior to the conventional time-to-peak methods.(7,9) Among these, one 110 
approach is assessment of mechanical activation delay by cross correlation analysis (CCA) using 111 
tissue Doppler Imaging (TDI).(7,10) Presence of a delayed mechanical activation by CCA in the 112 
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wide QRS patients is associated with improved prognosis as well as response after 113 
CRT.(7,10,11) However, its significance is unknown in HF patients with narrow QRS (<130 ms) 114 
treated with CRT. Accordingly, the objective of the current study was to assess the association of 115 
delayed mechanical activation by the CCA method both at baseline and follow-up after 116 
randomization to clinical outcomes in patients enrolled in the EchoCRT trial. 117 
Methods 118 
Study Population 119 
The current study is a pre-specified sub-study of the EchoCRT trial. All the patients 120 
included in the EchoCRT trial had left ventricular ejection fraction (LVEF) ≤ 35%, QRS 121 
duration of ≤ 130 ms, severe symptomatic HF with New York HF Association (NYHA) class III-122 
IV symptoms, LV end diastolic diameter ≥ 55 mm, and echocardiographic evidence of 123 
mechanical dyssynchrony by time-to-peak methods. Methods used to identify dyssynchrony in 124 
this study were presence of TDI based opposing wall delay of ≥ 80 ms in the apical 4-chamber or 125 
3-chamber view, and radial strain delay ≥ 130 ms between the septum and the posterior walls in 126 
the LV mid-segment short axis view. All the patients included in the trial were older than 18 127 
years and provided informed consent for inclusion in the trial. It was a multicenter randomized 128 
trial in which patients were included between a period of 2008 to 2013 and involved 112 centers 129 
from 22 different countries. Patients with bradycardia pacing or atrial fibrillation with in the past 130 
few months were excluded. The main study results along with a detailed study protocol have 131 
been published.(4) All the patients included received a CRT device with defibrillator capacity 132 
(CRT-D) (Biotronik Lumax, Berlin, Germany) and randomized in 1:1 fashion to CRT-On and 133 
CRT-Off after a successful implantation of the device. For the current sub-study, 807 (99.7%) of 134 
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809 were included with the baseline data and 610 (96%) of 635 patients were included with 135 
paired data at both baseline and 6-months follow-up.  136 
Cross correlation analysis 137 
All the echocardiograms were performed using a single vendor ultrasound system GE 138 
Vivid 7 or E9, Horton, Norway. To reduce variability the offline TDI based analysis was 139 
performed on a single GE EchoPAC system (version BT 11, Horton, Norway) by a single 140 
observer blinded to the patient data. CCA has been illustrated in detail in our previous 141 
publications (Figure 1).(7,10,11) Briefly, regions of interest (7 x 15 mm) were placed on the base 142 
segments of the opposing walls in all three apical views and the resulting velocity data were 143 
imported on an automated excel sheet with a pre-written algorithm to perform CCA analysis. 144 
Subsequently, velocity data were converted to acceleration data by using time differentiation. A 145 
baseline correlation coefficient was calculated between the acceleration curves from two 146 
opposing walls during systole in each of the three apical views without time-shift. These 147 
acceleration curves were then time-shifted against each other frame-by-frame to maximum of 15 148 
frames in both directions to calculate a correlation coefficient again. The time-shift resulting in 149 
the maximum correlation between the opposing walls was termed as maximum activation-delay 150 
(AD-max). Patients were classified as having significant activation delay if the AD-max was 151 
≥35ms in any of the three apical views based on our previous work.(7,10) Systole was identified 152 
by calculating the aortic valve opening and closure timings from a pulse Doppler signal in the 153 
APLAX view. Activation delay by CCA was measured at both baseline and 6-months. For the 154 
analysis of the patients with paired CCA data, patients were divided into the following four 155 
groups based on the presence or absence of mechanical activation at baseline and follow-up: 156 
1. No activation delay: no activation delay at both baseline and at follow-up. 157 
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2. Improved activation delay: activation delay at baseline but not at follow-up 158 
3. Persistent activation delay: activation delay at baseline and at follow-up 159 
4. New activation delay: no activation delay at baseline but activation delay at follow-160 
up. 161 
Study outcome 162 
The outcome variable of this study was the primary end-point of all-cause death or first 163 
HF hospitalization within a period of 3.5 years.  164 
Statistics  165 
 All the statistical analyses were performed by an independent Statistical Centre at the 166 
Robertson Centre for Biostatistics, University of Glasgow. Baseline characteristics were 167 
compared with the use of analysis of variance tests or chi-square tests for continuous and 168 
categorical variables respectively. Hazard ratios for CRT-On and CRT-Off with 95% confidence 169 
intervals were calculated with the Cox proportional hazards models for treatment effect and 170 
country of recruitment as a covariate. The interaction between delay subgroup and randomized 171 
treatment group was tested in a Cox model that included delay subgroup and treatment main 172 
effect and interaction terms. Time-to-event curves were estimated using the method of Kaplan 173 
and Meier.  174 
Results 175 
Among the 807 patients with baseline CCA analysis data, they were equally distributed 176 
with 404 (50.1%) patients in the CRT-Off group and 403 (49.9%) in the CRT-On group. Of 177 
these 807 patients, time-to-peak dyssynchrony data was available in 806 patients. Among these, 178 
420 (52%) patients had dyssynchrony by both radial strain and TDI opposing wall delay, 201 179 
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(25%) had dyssynchrony by lone TDI, and rest 185 (23%) patients had dyssynchrony by lone 180 
radial strain. A significant mechanical activation delay by CCA was observed in 223 (55%) 181 
patients among the CRT-Off patients and in 209 (52%) among the CRT-On patients. The 182 
baseline characteristics of the patients in the CRT-Off and CRT-On based on activation delay are 183 
summarized in Table 1. No significant differences were observed between the groups for the 184 
baseline characteristics. 185 
Association of baseline mechanical activation delay by CCA to long-term outcome 186 
The trial was stopped due to futility on advice of the independent data and monitoring 187 
board. The median follow-up period was 1.15 years (interquartile range 0.48 to 2.05 years). HF 188 
hospitalizations and all-cause death were observed in 216 (27%) patients by the time the trial 189 
was stopped. Separately, there were 187 HF hospitalizations and 29 deaths in the follow-up 190 
interval of 3.5 years. On dividing the patients into four groups, it was observed that patients with 191 
no mechanical activation delay by CCA in the CRT-On group suffered the highest number 192 
(32%) of events (Figure 2). Among patients with no mechanical activation delay, patients 193 
randomized to CRT-On group had an increased risk of an unfavorable outcome in comparison 194 
to those with CRT-Off with a HR 1.7 (95% CI 1.13-2.55, P=0.01; Figure 3). However, among 195 
patients with presence of activation delay, no significant difference was observed for events 196 
among the two CRT randomization groups (HR 0.96, 95% CI 0.66-1.40, P=0.84). Importantly, 197 
there was a significant interaction term between activation delay by CCA and randomization to 198 
CRT device for the outcome events (P=0.04).  199 
Changes in mechanical activation delay associated with outcome 200 
 At 6-months follow-up, echocardiographic data for the CCA was available in 610 (96%) 201 
patients out of 635 patients with follow-up echocardiograms. After excluding patients who had 202 
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already suffered HF hospitalization before the 6 months follow-up analysis, a final number of 203 
541 patients were available for follow-up analysis. Among these, 274 (51%) had CRT-Off and 204 
267 (49%) were from the CRT-On group. The distribution of the four groups based on 205 
mechanical activation delay at baseline and follow-up among patients with CRT-Off vs CRT-206 
On was similar:  no activation delay (31% vs. 30%), improved activation delay (27% vs. 31%), 207 
persistent activation delay (27% vs. 23%), and onset of new activation delay (15% vs.16%). 208 
 A total of 102 patients suffered either HF hospitalization or death from 6 months until 209 
completed follow-up excluding events that occurred in the first 6 months. The event rate was 210 
significantly higher among patients with a new mechanical activation delay observed on the 6 211 
months echocardiogram in the CRT-On group in comparison to the CRT-Off group (30% vs 212 
12%; HR 3.73, 95% CI 1.15-12.14, P=0.03; Figure 4). No significant difference was observed 213 
for the outcome events between the other three groups based on randomization.  214 
Discussion  215 
This pre-specified sub-study of the EchoCRT trial of HF patients with narrow QRS width 216 
shows that the absence of mechanical activation delay by CCA at baseline and new onset 217 
activation delay observed in follow-up in patients treated with CRT was significantly associated 218 
with poor clinical outcomes. These results support the notion that delayed activation by CCA is 219 
measuring a different mechanical phenomenon than time-to-peak dyssynchrony. These 220 
observations may provide new insight in the interpretation of EchoCRT trial and mechanistic 221 
working of CRT in general. 222 
The EchoCRT trial used the best documented methods for dyssynchrony for selection of 223 
patients at the time of study design, i.e. both longitudinal TDI velocity and 2D STE radial strain 224 
time to peak assessment. In HF patients with wide QRS, these methods have been demonstrated 225 
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to be of additive prognostic value.(1,2,12) Moreover, single center studies using these methods 226 
have shown that narrow QRS HF patients having echocardiographic dyssynchrony treated by 227 
CRT device have improvement in HF symptoms and LV reverse remodeling comparable to 228 
patients with wide QRS.(13,14) Meanwhile, questions have been raised regarding the specificity 229 
of these methods.(4-6,10) Time to peak measurements alone do not provide any information on 230 
the nature of the wall deformation such as whether differences are due to scarring or activation 231 
timing differences.(6) Although time-to-peak differences due to abnormalities in the myocardial 232 
tissue is demonstrated to have prognostic significance in various types of 233 
cardiomyopathies,(15,16) it is not correctable by CRT specifically in the absence of concomitant 234 
electrical dyssynchrony.(4,5) Our results of the current analysis strengthen the view that peak-to-235 
peak methods are relatively nonspecific for detecting true dyssynchrony responsive to CRT, as 236 
only one-half of the patients included in EchoCRT trial had significant mechanical activation 237 
delay by CCA. Mechanical activation delay by CCA may be less susceptible to differences in 238 
mechanical motion patterns not caused by delayed activation.(7,10) CCA analysis in wide QRS 239 
complex patients undergoing CRT have proven beneficial in identifying responders having both 240 
wide and intermediate QRS durations and has been demonstrated to be able to evaluate 241 
resynchronization efficacy to obtain maximum CRT benefit.(7,10,11)  242 
Unlike CCA method which is more of a quantitative approach, other methods which are 243 
qualitative in nature for the assessment of dyssynchrony, such as identification of typical 244 
contraction pattern (9) and  apical rocking (17) are proposed to identify the true left bundle 245 
branch block (LBBB) patients with activation delay. Both these methods have shown excellent 246 
additional value in identifying potential responders to CRT in patients with left bundle branch 247 
block (LBBB) which is principally due to exclusion of patients who are misdiagnosed as LBBB 248 
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by ECG. However, this unique contraction pattern of the opposing walls described by Risum et 249 
al (9) is specific to patients with true LBBB and would be physiologically implausible in other 250 
kinds of cardiomyopathy.  On the other hand, dyssynchrony by CCA quantifies the activation 251 
delay between two opposing walls rather than relying on a specific contraction pattern and thus 252 
could be applicable in patients other than LBBB. It has not only demonstrated to be superior to 253 
TDI time-to-peak in wide QRS patients in predicting survival after CRT but has also shown 254 
promising results in the intermediate QRS (120-149 ms) patients.(7)  255 
It seems, however, that even when selecting patients with the stricter CCA-criteria for 256 
mechanical activation delay, there is no convincing positive effect of CRT in HF patients with 257 
narrow QRS. One possible explanation could be that mechanical activation delay in the setting 258 
of narrow QRS needs not represent a substrate amenable to CRT. The follow-up CCA-analysis 259 
agrees with this interpretation, as CRT was inefficient in correcting mechanical activation delay 260 
in a large group of patients. Even though CCA is less susceptible to other motion differences 261 
between LV walls, it is likely that mechanical activation can be delayed for other reasons than 262 
delays in electrical activation, such as differences in electro-mechanical coupling. It should also 263 
be considered that the study sample size was reduced by premature termination of the trial, and 264 
there are relatively wide confidence limits to these subgroup estimates of treatment effect.  265 
The strongest signal of our analysis is the suggestion of a harmful effect of CRT isolated 266 
to patients with no activation delay at baseline by CCA. This is an important finding given the 267 
higher mortality observed in the CRT-On group in EchoCRT. Follow-up evaluation confirmed 268 
that especially patients without activation delay randomized to CRT-On who developed new 269 
activation delay had a significantly worse outcome, with an almost 4-fold increased risk of 270 
adverse events. Similar observation have been made regarding new or worsened activation delay 271 
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during CRT in patients with a wide QRS.(11,18-20) This finding of potential harm from CRT in 272 
patients without baseline mechanical activation delay also fits well with a previous study of 273 
CCA in intermediate to wide QRS HF patients treated with CRT, where lack of baseline 274 
activation delay was associated with a poor long-term outcome.(7)  275 
There are several interesting perspectives in the present analysis. Firstly, when 276 
considering HF patients with narrow QRS ≤ 130 ms, it seems the prevalence of potential 277 
responders to CRT is quite low, and will be hard to identify, even with advanced methods such 278 
as CCA. Secondly, in HF patients with intermediate QRS 130-149 ms, the prevalence of 279 
potential responders is probably higher, and as the effect of CRT overall in this group is less 280 
well established, there could be a role for methods such as CCA to select patients for CRT in 281 
future trials. Thirdly, in HF patients with intermediate or broad QRS > 150 ms, CCA seems an 282 
attractive method for detecting patients that are potentially harmed by CRT. This sets the stage 283 
for potential trials in the future of deferral of CRT in patients without mechanical activation 284 
delay, or trials of turning off CRT in patients where new-onset mechanical activation delay 285 
cannot be corrected by optimization. 286 
Limitations 287 
The current study is a post-hoc study. Although it was a pre-specified sub-study which 288 
was approved before the study commenced, the method applied in the study was not a part of 289 
the patient selection process for the trial. Another limitation of the study was the lack of 6-290 
months follow-up echocardiograms in many patients, 610 patients had 6-months follow 291 
echocardiograms for the CCA resulting into a loss of about 24% patients for the follow-up 292 
analysis. This was mostly due to the premature closure of the study.  293 
Conclusions 294 
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In conclusion, the effect of CRT in HF patients with narrow QRS (≤ 130ms) in terms of 295 
HF hospitalization and death depends on left ventricular mechanical activation delay determined 296 
by echocardiographic CCA. CRT specifically resulted in poor outcome in HF patients with 297 
narrow QRS and no activation delay by CCA at baseline which is most probably caused by the 298 
pacing-induced development of new activation delay. This study provides new mechanistic 299 
insight into effects of CRT pacing in HF patients which is of clinical significance. 300 
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Perspectives 319 
Competency In Medical Knowledge: This study demonstrates the limitation of the time-to-320 
peak based dyssynchrony measures which are applied in the routine clinical practice. Nearly, 321 
45% patients did not have significant activation delay by cross correlation analysis (CCA) when 322 
applied on the patients selected in the EchoCRT trial who were included based on the 323 
dyssynchrony by time-to-peak based methods. CRT was particularly fatal to patients with 324 
narrow QRS who lacked activation delay at baseline by CCA due to the risk of pacemaker 325 
induced new activation delay. 326 
Translational Outlook: Further randomized studies applying this method specifically in 327 
patients with intermediate QRS duration (120-140 ms) where the guidelines are unclear about 328 
CRT implantation would be beneficial. 329 
 330 
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 341 
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Figure Legends 416 
Central illustration: Cross correlation analysis by Tissue Doppler Imaging and outcome in 417 
narrow QRS patients treated with cardiac resynchronization therapy 418 
Left panel shows increased hospitalization due to HF and mortality in patients with no activation 419 
delay at baseline and implanted with CRT with a significant interaction between device 420 
randomization and activation delay for the end-points. Right Panel shows that patients with new 421 
activation delay after CRT in comparison to those with no CRT had poor outcome indicating the 422 
role of device induced activation delay in the poor prognosis. 423 
Figure 1:  Examples comparing dyssynchrony by time-ot-peak and activation delay by cross 424 
correlation analysis 425 
Two examples from the trial showing dyssynchrony by time-to-peak (≥ 80 ms) opposing wall 426 
delay using the tissue Doppler imaging. However, only the patient in the upper panel has a 427 
significant activation delay (≥ 35 ms) on cross correlation analysis (CCA). The patient in the 428 
lower panel has nearly no activation delay (6 ms). This can be visually appreciated when we 429 
compare the acceleration curves of the septum and lateral walls (third column) of the two panels.    430 
Figure 2: Baseline activation delay and Outcome 431 
Bar diagram showing the incidence of events of heart failure hospitalization or death among the 432 
two CRT device randomization groups based on the activation delay. 433 
Figure 3: Baseline activation delay and time to events 434 
Kaplan Meier curve showing the time to events for the four patient groups based on the presence 435 
or absence of activation delay at baseline and CRT device randomization. 436 
Figure 4: Change in activation delay and Outcome after 6-months of CRT implantation 437 
Bar diagram showing the comparative incidence of outcome events between CRT-Off and CRT-438 
On after 6-months of device implantation among the four patients groups based on the presence 439 
or absence of activation delay at baseline and 6-months follow-up. Only patients with no events 440 
in the first 6-months of device implantation were included in this analysis. 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
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Table 1 Baseline Characteristics 450 
Variables CRT-Off with No 
AD 
CRT-On with No 
AD 
CRT-Off with AD CRT-On with AD 
n Statistics n Statistics n Statistics n Statistics 
Age (years) 181 57.4 (11.72) 194 57.0 (13.07) 223 59.2 (13.12) 209 58.1 (12.77) 
Males (n) 181 127 (70.17%) 194 145 (74.74%) 223 163 (73.09%) 209 149 (71.29%) 
QRS width (ms) 180 104.0 (12.04) 192 106.1 (12.43) 221 106.7 (12.00) 205 105.9 (13.65) 
Walking distance (m) 175 317.5 (118.93) 192 330.7 (123.38) 219 326.9 (124.84) 204 325.7 (114.31) 
Quality of life score 181 55.2 (23.63) 194 51.5 (25.07) 221 47.5 (24.14) 208 51.3 (23.67) 
NYHA Classification (n) 181  194  223  209  
  I  1 (0.55%)  2 (1.03%)  2 (0.90%)  0 (0.00%) 
  II  5 (2.76%)  4 (2.06%)  7 (3.14%)  3 (1.44%) 
  III  170 (94%)  184 (95%)  204 (91%)  200 (96%) 
  IV  5 (2.76%)  4 (2.06%)  10 (4.48%)  6 (2.87%) 
BNP (pg/ml) 99 244 (89-613) 109 242 (40-493) 94 290 (126-600) 91 224 (115-564) 
NT-proBNP (pg/ml) 77 1071 (462-
2203) 
74 1121 (414-
2444) 
122 923 (529-
1999) 
110 1378 (556-
2675) 
Sitting SBP (mmHg) 181 118 (16) 194 118 (22) 223 122 (21) 209 117 (18) 
Sitting DBP (mmHg) 181 73 (11) 194 73 (13) 223 73 (13) 209 73 (12) 
BMI (kg/m2) 181 30 (7) 194 31 (15) 223 32 (16) 209 31 (7) 
Ischemic cardiomyopathy (n) 180 93 (52%) 194 99 (51%) 223 120 (54%) 209 119 (57%) 
MI > 3 months ago (n) 181 71 (39%) 194 69 (36%) 223 83 (37%) 209 98(47%) 
PCI > 3 months ago (n) 181 56 (31%) 194 74 (38%) 223 74 (33%) 209 98 (47%) 
CABG > 3 months ago (n) 181 35 (19%) 194 35 (18%) 223 39 (17%) 209 42 (20%) 
Hypertension (n) 178 119 (67%) 194 124 (64%) 223 151 (68% 205 137 (67%) 
Congenital heart disease (n) 175 3 (1.7%) 192 3 (1.6%) 220 7 (3.2%) 206 3 (1.5%) 
Prior ischemic stroke or TIA 
(n) 
180 28 (16%) 193 19 (10%) 221 19 (9%) 207 30 (14%) 
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Diabetes (n) 181 69 (38%) 193 77 (40%) 222 84 (38%) 208 89 (43%) 
Chronic lung disease (n) 180 33 (18%) 191 30 (16%) 220 45 (20%) 209 39 (19%) 
Chronic kidney disease (n) 180 17 (9%) 192 30 (16%) 220 25 (11%) 209 36 (17%) 
LV EF Biplane (%) 181 27.4 (5.3) 194 27.4 (5.5) 223 26.7 (5.6) 209 26.7 (5.8) 
LV end diastolic diameter 
(mm) 
181 66 (7) 194 67 (7) 223 67 (8) 209 67 (8) 
ACE inhibitor or ARB (n) 181 177 (98%) 194  185 (95%) 223 206 (92%) 209 197 (94%) 
Aldosterone antagonist (n) 181 105 (58%) 194  118 (61%) 223 132 (59%) 209  128 (61%) 
Beta-blocker (n) 181 178 (98%) 194 183 (94%) 223 216 (97%) 209 203 (97%) 
Diuretic agent (n) 181 160 (88%) 194 160 (82%) 223 191 (86%) 209 185 (88%) 
MR grade (n) 180  192  221  206  
  None/Trace  69 (38%)  64 (33%)  77 (35%)  69 (34%) 
  Mild  65 (36%)  80 (42%)  89 (40%)  83 (40%) 
  Moderate  25 (14%)  31 (16%)  34 (15%)  33 (16%) 
  Moderate/Severe  14 (8%)  11 (6%)  12 (5%)  14 (7%) 
  Severe  7 (4%)  6 (3%)  9 (4%)  7 (3%) 
LV ESV (ml) 180 134 (47) 194 140 (49) 223 142 (54) 207 142 (49) 
LV EDV (ml) 180 183 (57) 194 191 (58) 223 192 (65) 207 190 (55) 
TDI (ms) 181 97 (39) 194 98 (34) 223 105 (34) 208 104 (31) 
Speckle tracking (ms) 173 218 (109) 181 213 (100) 202 223 (102) 191 223 (99) 
AD= activation delay; NYHA= New York Heart Association; BNP= brain natriuretic peptide; SBP= 451 
systolic blood pressure; DBP= diastolic blood pressure; BMI= body mass index, MI= myocardial 452 
infarction; PCI= percutaneous coronary interventions; CABG= coronary artery bypass surgery; TIA= 453 
transient ischemic attack; LV= left ventricular; EF= ejection fraction; ACE= angiotensin converting 454 
enzyme; ARB= angiotensin II receptor blocker; MR= mitral regurgitation; EDV= end-diastolic volume; 455 
ESV= end-systolic volume; TDI= tissue Doppler imaging 456 
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Abstract 51 
 52 
Background: Cross Correlation Analysis (CCA) using tissue Doppler imaging (TDI) shown to 53 
be associated with outcome after cardiac resynchronization therapy (CRT) in heart failure (HF) 54 
patients with wide QRS. However, its significance in narrow QRS patients treated with CRT is 55 
unknown.  56 
Objectives: The aim of the current study was to investigate the association of mechanical 57 
activation delay by CCA with study outcome in HF patients enrolled in the EchoCRT trial. 58 
Methods: Baseline CCA could be performed from TDI in the apical views in 807 of 809 59 
(99.7%) enrolled patients while 6-months follow-up could be performed in 610 of 635 (96%) 60 
patients with available echocardiograms. Patients with a pre-specified maximal activation delay 61 
≥ 35 ms were considered to have significant delay. The study outcome was HF hospitalization or 62 
death. 63 
Results: Out of 807, 375 (46%) patients did not have delayed mechanical activation at baseline 64 
by CCA. Patients without delayed mechanical activation randomized to CRT-On had an 65 
increased risk of poor outcome (HR 1.70, 95% CI 1.13-2.55, P=0.01) in comparison to those 66 
with CRT-Off with a significant interaction term (P=0.04) between delayed mechanical 67 
activation and device randomization for the endpoint. Among patients with paired baseline and 68 
follow-up data with no events before 6-months follow-up (n=541), new-onset delayed 69 
mechanical activation in the CRT-On group showed significant increase in unfavorable events 70 
(HR 3.73, 95% CI 1.15-12.14, P=0.03). 71 
Conclusions: In the EchoCRT population, absence of delayed mechanical activation by CCA 72 
was significantly associated with poor outcomes possibly due to the onset of new delayed 73 
mechanical activation with CRT pacing. (Echocardiography Guided Cardiac Resynchronization 74 
Therapy [EchoCRT] Trial; NCT00683696) 75 
Key words: heart failure, cardiac resynchronization therapy, echocardiography, dyssynchrony, 76 
tissue Doppler imaging. 77 
Condensed Abstract 78 
In the current study we applied cross correlation analysis method (CCA) to assess mechanical 79 
activation delay in the population of echocardiography guided cardiac resynchronization therapy 80 
(EchoCRT) trial in which CRT was implanted in patients with narrow QRS (<130ms). CRT was 81 
fatal to patients with no activation delay at baseline which was possibly due to the pacemaker 82 
induced new activation delay.  83 
Abbreviation List 84 
CRT = cardiac resynchronization therapy 85 
ECG = electrocardiographic 86 
HF = heart failure  87 
LVEF = left ventricular ejection fraction 88 
TDI = tissue Doppler imaging 89 
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Several studies in the past have demonstrated that the assessment of mechanical 90 
dyssynchrony by echocardiography can supplement current electrocardiographic (ECG) criteria 91 
(wide QRS ≥ 120 ms) in selection of CRT candidates leading to an overall reduction in the non-92 
responders rate.(1-3) However, conventional methods of identifying dyssynchrony based on 93 
segmental time-to-peak measurements have failed when applied in randomized trials for 94 
selecting patients for CRT with narrow QRS (<130ms).(4,5) 95 
The largest CRT trial conducted on narrow QRS (<130 ms) patients - echocardiography 96 
guided cardiac resynchronization therapy (EchoCRT) - demonstrated that HF patients with 97 
narrow QRS (<130 ms) do not respond to CRT despite the presence of baseline mechanical 98 
dyssynchrony by time-to-peak methods by either tissue Doppler longitudinal velocity or speckle 99 
tracking radial strain.(4) In fact, an increased incidence of mortality was observed in patients 100 
randomized to CRT-On in comparison to the control group and the trial was stopped due to 101 
futility without achieving its complete target population. Another trial - The Resynchronization 102 
therapy in narrow QRS (RethinQ) - performed before EchoCRT with similar design where 103 
mechanical dyssynchrony was one of the selection criteria, also showed no benefit of CRT in HF 104 
patients with narrow QRS.(5)    105 
More recently, it was shown that peak-to-peak measures of mechanical dyssynchrony 106 
may be influenced by contractile heterogeneity or scar not responsive to CRT.(6) Patterns of 107 
myocardial mechanics that have been shown to reflect electrical delay have shown very 108 
promising results and seem to better identify a true substrate for CRT response.(6-8) These 109 
newer methods seem superior to the conventional time-to-peak methods.(7,9) Among these, one 110 
approach is assessment of mechanical activation delay by cross correlation analysis (CCA) using 111 
tissue Doppler Imaging (TDI).(7,10) Presence of a delayed mechanical activation by CCA in the 112 
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wide QRS patients is associated with improved prognosis as well as response after 113 
CRT.(7,10,11) However, its significance is unknown in HF patients with narrow QRS (<130 ms) 114 
treated with CRT. Accordingly, the objective of the current study was to assess the association of 115 
delayed mechanical activation by the CCA method both at baseline and follow-up after 116 
randomization to clinical outcomes in patients enrolled in the EchoCRT trial. 117 
Methods 118 
Study Population 119 
The current study is a pre-specified sub-study of the EchoCRT trial. All the patients 120 
included in the EchoCRT trial had left ventricular ejection fraction (LVEF) ≤ 35%, QRS 121 
duration of ≤ 130 ms, severe symptomatic HF with New York HF Association (NYHA) class III-122 
IV symptoms, LV end diastolic diameter ≥ 55 mm, and echocardiographic evidence of 123 
mechanical dyssynchrony by time-to-peak methods. Methods used to identify dyssynchrony in 124 
this study were presence of TDI based opposing wall delay of ≥ 80 ms in the apical 4-chamber or 125 
3-chamber view, and radial strain delay ≥ 130 ms between the septum and the posterior walls in 126 
the LV mid-segment short axis view. All the patients included in the trial were older than 18 127 
years and provided informed consent for inclusion in the trial. It was a multicenter randomized 128 
trial in which patients were included between a period of 2008 to 2013 and involved 112 centers 129 
from 22 different countries. Patients with bradycardia pacing or atrial fibrillation with in the past 130 
few months were excluded. The main study results along with a detailed study protocol have 131 
been published.(4) All the patients included received a CRT device with defibrillator capacity 132 
(CRT-D) (Biotronik Lumax, Berlin, Germany) and randomized in 1:1 fashion to CRT-On and 133 
CRT-Off after a successful implantation of the device. For the current sub-study, 807 (99.7%) of 134 
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809 were included with the baseline data and 610 (96%) of 635 patients were included with 135 
paired data at both baseline and 6-months follow-up.  136 
Cross correlation analysis 137 
All the echocardiograms were performed using a single vendor ultrasound system GE 138 
Vivid 7 or E9, Horton, Norway. To reduce variability the offline TDI based analysis was 139 
performed on a single GE EchoPAC system (version BT 11, Horton, Norway) by a single 140 
observer blinded to the patient data. CCA has been illustrated in detail in our previous 141 
publications (Figure 1).(7,10,11) Briefly, regions of interest (7 x 15 mm) were placed on the base 142 
segments of the opposing walls in all three apical views and the resulting velocity data were 143 
imported on an automated excel sheet with a pre-written algorithm to perform CCA analysis. 144 
Subsequently, velocity data were converted to acceleration data by using time differentiation. A 145 
baseline correlation coefficient was calculated between the acceleration curves from two 146 
opposing walls during systole in each of the three apical views without time-shift. These 147 
acceleration curves were then time-shifted against each other frame-by-frame to maximum of 15 148 
frames in both directions to calculate a correlation coefficient again. The time-shift resulting in 149 
the maximum correlation between the opposing walls was termed as maximum activation-delay 150 
(AD-max). Patients were classified as having significant activation delay if the AD-max was 151 
≥35ms in any of the three apical views based on our previous work.(7,10) Systole was identified 152 
by calculating the aortic valve opening and closure timings from a pulse Doppler signal in the 153 
APLAX view. Activation delay by CCA was measured at both baseline and 6-months. For the 154 
analysis of the patients with paired CCA data, patients were divided into the following four 155 
groups based on the presence or absence of mechanical activation at baseline and follow-up: 156 
1. No activation delay: no activation delay at both baseline and at follow-up. 157 
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2. Improved activation delay: activation delay at baseline but not at follow-up 158 
3. Persistent activation delay: activation delay at baseline and at follow-up 159 
4. New activation delay: no activation delay at baseline but activation delay at follow-160 
up. 161 
Study outcome 162 
The outcome variable of this study was the primary end-point of all-cause death or first 163 
HF hospitalization within a period of 3.5 years.  164 
Statistics  165 
 All the statistical analyses were performed by an independent Statistical Centre at the 166 
Robertson Centre for Biostatistics, University of Glasgow. Baseline characteristics were 167 
compared with the use of analysis of variance tests or chi-square tests for continuous and 168 
categorical variables respectively. Hazard ratios for CRT-On and CRT-Off with 95% confidence 169 
intervals were calculated with the Cox proportional hazards models for treatment effect and 170 
country of recruitment as a covariate. The interaction between delay subgroup and randomized 171 
treatment group was tested in a Cox model that included delay subgroup and treatment main 172 
effect and interaction terms. Time-to-event curves were estimated using the method of Kaplan 173 
and Meier.  174 
Results 175 
Among the 807 patients with baseline CCA analysis data, they were equally distributed 176 
with 404 (50.1%) patients in the CRT-Off group and 403 (49.9%) in the CRT-On group. Of 177 
these 807 patients, time-to-peak dyssynchrony data was available in 806 patients. Among these, 178 
420 (52%) patients had dyssynchrony by both radial strain and TDI opposing wall delay, 201 179 
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(25%) had dyssynchrony by lone TDI, and rest 185 (23%) patients had dyssynchrony by lone 180 
radial strain. A significant mechanical activation delay by CCA was observed in 223 (55%) 181 
patients among the CRT-Off patients and in 209 (52%) among the CRT-On patients. The 182 
baseline characteristics of the patients in the CRT-Off and CRT-On based on activation delay are 183 
summarized in Table 1. No significant differences were observed between the groups for the 184 
baseline characteristics. 185 
Association of baseline mechanical activation delay by CCA to long-term outcome 186 
The trial was stopped due to futility on advice of the independent data and monitoring 187 
board. The median follow-up period was 1.15 years (interquartile range 0.48 to 2.05 years). HF 188 
hospitalizations and all-cause death were observed in 216 (27%) patients by the time the trial 189 
was stopped. Separately, there were 187 HF hospitalizations and 29 deaths in the follow-up 190 
interval of 3.5 years. On dividing the patients into four groups, it was observed that patients with 191 
no mechanical activation delay by CCA in the CRT-On group suffered the highest number 192 
(32%) of events (Figure 2). Among patients with no mechanical activation delay, patients 193 
randomized to CRT-On group had an increased risk of an unfavorable outcome in comparison 194 
to those with CRT-Off with a HR 1.7 (95% CI 1.13-2.55, P=0.01; Figure 3). However, among 195 
patients with presence of activation delay, no significant difference was observed for events 196 
among the two CRT randomization groups (HR 0.96, 95% CI 0.66-1.40, P=0.84). Importantly, 197 
there was a significant interaction term between activation delay by CCA and randomization to 198 
CRT device for the outcome events (P=0.04).  199 
Changes in mechanical activation delay associated with outcome 200 
 At 6-months follow-up, echocardiographic data for the CCA was available in 610 (96%) 201 
patients out of 635 patients with follow-up echocardiograms. After excluding patients who had 202 
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already suffered HF hospitalization before the 6 months follow-up analysis, a final number of 203 
541 patients were available for follow-up analysis. Among these, 274 (51%) had CRT-Off and 204 
267 (49%) were from the CRT-On group. The distribution of the four groups based on 205 
mechanical activation delay at baseline and follow-up among patients with CRT-Off vs CRT-206 
On was similar:  no activation delay (31% vs. 30%), improved activation delay (27% vs. 31%), 207 
persistent activation delay (27% vs. 23%), and onset of new activation delay (15% vs.16%). 208 
 A total of 102 patients suffered either HF hospitalization or death from 6 months until 209 
completed follow-up excluding events that occurred in the first 6 months. The event rate was 210 
significantly higher among patients with a new mechanical activation delay observed on the 6 211 
months echocardiogram in the CRT-On group in comparison to the CRT-Off group (30% vs 212 
12%; HR 3.73, 95% CI 1.15-12.14, P=0.03; Figure 4). No significant difference was observed 213 
for the outcome events between the other three groups based on randomization.  214 
Discussion  215 
This pre-specified sub-study of the EchoCRT trial of HF patients with narrow QRS width 216 
shows that the absence of mechanical activation delay by CCA at baseline and new onset 217 
activation delay observed in follow-up in patients treated with CRT was significantly associated 218 
with poor clinical outcomes. These results support the notion that delayed activation by CCA is 219 
measuring a different mechanical phenomenon than time-to-peak dyssynchrony. These 220 
observations may provide new insight in the interpretation of EchoCRT trial and mechanistic 221 
working of CRT in general. 222 
The EchoCRT trial used the best documented methods for dyssynchrony for selection of 223 
patients at the time of study design, i.e. both longitudinal TDI velocity and 2D STE radial strain 224 
time to peak assessment. In HF patients with wide QRS, these methods have been demonstrated 225 
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to be of additive prognostic value.(1,2,12) Moreover, single center studies using these methods 226 
have shown that narrow QRS HF patients having echocardiographic dyssynchrony treated by 227 
CRT device have improvement in HF symptoms and LV reverse remodeling comparable to 228 
patients with wide QRS.(13,14) Meanwhile, questions have been raised regarding the specificity 229 
of these methods.(4-6,10) Time to peak measurements alone do not provide any information on 230 
the nature of the wall deformation such as whether differences are due to scarring or activation 231 
timing differences.(6) Although time-to-peak differences due to abnormalities in the myocardial 232 
tissue is demonstrated to have prognostic significance in various types of 233 
cardiomyopathies,(15,16) it is not correctable by CRT specifically in the absence of concomitant 234 
electrical dyssynchrony.(4,5) Our results of the current analysis strengthen the view that peak-to-235 
peak methods are relatively nonspecific for detecting true dyssynchrony responsive to CRT, as 236 
only one-half of the patients included in EchoCRT trial had significant mechanical activation 237 
delay by CCA. Mechanical activation delay by CCA may be less susceptible to differences in 238 
mechanical motion patterns not caused by delayed activation.(7,10) CCA analysis in wide QRS 239 
complex patients undergoing CRT have proven beneficial in identifying responders having both 240 
wide and intermediate QRS durations and has been demonstrated to be able to evaluate 241 
resynchronization efficacy to obtain maximum CRT benefit.(7,10,11)  242 
Unlike CCA method which is more of a quantitative approach, other methods which are 243 
qualitative in nature for the assessment of dyssynchrony, such as identification of typical 244 
contraction pattern (9) and  apical rocking (17) are proposed to identify the true left bundle 245 
branch block (LBBB) patients with activation delay. Both these methods have shown excellent 246 
additional value in identifying potential responders to CRT in patients with left bundle branch 247 
block (LBBB) which is principally due to exclusion of patients who are misdiagnosed as LBBB 248 
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by ECG. However, this unique contraction pattern of the opposing walls described by Risum et 249 
al (9) is specific to patients with true LBBB and would be physiologically implausible in other 250 
kinds of cardiomyopathy.  On the other hand, dyssynchrony by CCA quantifies the activation 251 
delay between two opposing walls rather than relying on a specific contraction pattern and thus 252 
could be applicable in patients other than LBBB. It has not only demonstrated to be superior to 253 
TDI time-to-peak in wide QRS patients in predicting survival after CRT but has also shown 254 
promising results in the intermediate QRS (120-149 ms) patients.(7)  255 
It seems, however, that even when selecting patients with the stricter CCA-criteria for 256 
mechanical activation delay, there is no convincing positive effect of CRT in HF patients with 257 
narrow QRS. One possible explanation could be that mechanical activation delay in the setting 258 
of narrow QRS needs not represent a substrate amenable to CRT. The follow-up CCA-analysis 259 
agrees with this interpretation, as CRT was inefficient in correcting mechanical activation delay 260 
in a large group of patients. Even though CCA is less susceptible to other motion differences 261 
between LV walls, it is likely that mechanical activation can be delayed for other reasons than 262 
delays in electrical activation, such as differences in electro-mechanical coupling. It should also 263 
be considered that the study sample size was reduced by premature termination of the trial, and 264 
there are relatively wide confidence limits to these subgroup estimates of treatment effect.  265 
The strongest signal of our analysis is the suggestion of a harmful effect of CRT isolated 266 
to patients with no activation delay at baseline by CCA. This is an important finding given the 267 
higher mortality observed in the CRT-On group in EchoCRT. Follow-up evaluation confirmed 268 
that especially patients without activation delay randomized to CRT-On who developed new 269 
activation delay had a significantly worse outcome, with an almost 4-fold increased risk of 270 
adverse events. Similar observation have been made regarding new or worsened activation delay 271 
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during CRT in patients with a wide QRS.(11,18-20) This finding of potential harm from CRT in 272 
patients without baseline mechanical activation delay also fits well with a previous study of 273 
CCA in intermediate to wide QRS HF patients treated with CRT, where lack of baseline 274 
activation delay was associated with a poor long-term outcome.(7)  275 
There are several interesting perspectives in the present analysis. Firstly, when 276 
considering HF patients with narrow QRS ≤ 130 ms, it seems the prevalence of potential 277 
responders to CRT is quite low, and will be hard to identify, even with advanced methods such 278 
as CCA. Secondly, in HF patients with intermediate QRS 130-149 ms, the prevalence of 279 
potential responders is probably higher, and as the effect of CRT overall in this group is less 280 
well established, there could be a role for methods such as CCA to select patients for CRT in 281 
future trials. Thirdly, in HF patients with intermediate or broad QRS > 150 ms, CCA seems an 282 
attractive method for detecting patients that are potentially harmed by CRT. This sets the stage 283 
for potential trials in the future of deferral of CRT in patients without mechanical activation 284 
delay, or trials of turning off CRT in patients where new-onset mechanical activation delay 285 
cannot be corrected by optimization. 286 
Limitations 287 
The current study is a post-hoc study. Although it was a pre-specified sub-study which 288 
was approved before the study commenced, the method applied in the study was not a part of 289 
the patient selection process for the trial. Another limitation of the study was the lack of 6-290 
months follow-up echocardiograms in many patients, 610 patients had 6-months follow 291 
echocardiograms for the CCA resulting into a loss of about 24% patients for the follow-up 292 
analysis. This was mostly due to the premature closure of the study.  293 
Conclusions 294 
12 
 
In conclusion, the effect of CRT in HF patients with narrow QRS (≤ 130ms) in terms of 295 
HF hospitalization and death depends on left ventricular mechanical activation delay determined 296 
by echocardiographic CCA. CRT specifically resulted in poor outcome in HF patients with 297 
narrow QRS and no activation delay by CCA at baseline which is most probably caused by the 298 
pacing-induced development of new activation delay. This study provides new mechanistic 299 
insight into effects of CRT pacing in HF patients which is of clinical significance. 300 
 301 
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Perspectives 319 
Competency In Medical Knowledge: This study demonstrates the limitation of the time-to-320 
peak based dyssynchrony measures which are applied in the routine clinical practice. Nearly, 321 
45% patients did not have significant activation delay by cross correlation analysis (CCA) when 322 
applied on the patients selected in the EchoCRT trial who were included based on the 323 
dyssynchrony by time-to-peak based methods. CRT was particularly fatal to patients with 324 
narrow QRS who lacked activation delay at baseline by CCA due to the risk of pacemaker 325 
induced new activation delay. 326 
Translational Outlook: Further randomized studies applying this method specifically in 327 
patients with intermediate QRS duration (120-140 ms) where the guidelines are unclear about 328 
CRT implantation would be beneficial. 329 
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Figure Legends 416 
Central illustration: Cross correlation analysis by Tissue Doppler Imaging and outcome in 417 
narrow QRS patients treated with cardiac resynchronization therapy 418 
Left panel shows increased hospitalization due to HF and mortality in patients with no activation 419 
delay at baseline and implanted with CRT with a significant interaction between device 420 
randomization and activation delay for the end-points. Right Panel shows that patients with new 421 
activation delay after CRT in comparison to those with no CRT had poor outcome indicating the 422 
role of device induced activation delay in the poor prognosis. 423 
Figure 1:  Examples comparing dyssynchrony by time-ot-peak and activation delay by cross 424 
correlation analysis 425 
Two examples from the trial showing dyssynchrony by time-to-peak (≥ 80 ms) opposing wall 426 
delay using the tissue Doppler imaging. However, only the patient in the upper panel has a 427 
significant activation delay (≥ 35 ms) on cross correlation analysis (CCA). The patient in the 428 
lower panel has nearly no activation delay (6 ms). This can be visually appreciated when we 429 
compare the acceleration curves of the septum and lateral walls (third column) of the two panels.    430 
Figure 2: Baseline activation delay and Outcome 431 
Bar diagram showing the incidence of events of heart failure hospitalization or death among the 432 
two CRT device randomization groups based on the activation delay. 433 
Figure 3: Baseline activation delay and time to events 434 
Kaplan Meier curve showing the time to events for the four patient groups based on the presence 435 
or absence of activation delay at baseline and CRT device randomization. 436 
Figure 4: Change in activation delay and Outcome after 6-months of CRT implantation 437 
Bar diagram showing the comparative incidence of outcome events between CRT-Off and CRT-438 
On after 6-months of device implantation among the four patients groups based on the presence 439 
or absence of activation delay at baseline and 6-months follow-up. Only patients with no events 440 
in the first 6-months of device implantation were included in this analysis. 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
Table 1 Baseline Characteristics 449 
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Variables CRT-Off with No 
AD 
CRT-On with No 
AD 
CRT-Off with AD CRT-On with AD 
n Statistics n Statistics n Statistics n Statistics 
Age (years) 181 57.4 (11.72) 194 57.0 (13.07) 223 59.2 (13.12) 209 58.1 (12.77) 
Males (n) 181 127 (70.17%) 194 145 (74.74%) 223 163 (73.09%) 209 149 (71.29%) 
QRS width (ms) 180 104.0 (12.04) 192 106.1 (12.43) 221 106.7 (12.00) 205 105.9 (13.65) 
Walking distance (m) 175 317.5 (118.93) 192 330.7 (123.38) 219 326.9 (124.84) 204 325.7 (114.31) 
Quality of life score 181 55.2 (23.63) 194 51.5 (25.07) 221 47.5 (24.14) 208 51.3 (23.67) 
NYHA Classification (n) 181  194  223  209  
  I  1 (0.55%)  2 (1.03%)  2 (0.90%)  0 (0.00%) 
  II  5 (2.76%)  4 (2.06%)  7 (3.14%)  3 (1.44%) 
  III  170 (94%)  184 (95%)  204 (91%)  200 (96%) 
  IV  5 (2.76%)  4 (2.06%)  10 (4.48%)  6 (2.87%) 
BNP (pg/ml) 99 244 (89-613) 109 242 (40-493) 94 290 (126-600) 91 224 (115-564) 
NT-proBNP (pg/ml) 77 1071 (462-
2203) 
74 1121 (414-
2444) 
122 923 (529-
1999) 
110 1378 (556-
2675) 
Sitting SBP (mmHg) 181 118 (16) 194 118 (22) 223 122 (21) 209 117 (18) 
Sitting DBP (mmHg) 181 73 (11) 194 73 (13) 223 73 (13) 209 73 (12) 
BMI (kg/m2) 181 30 (7) 194 31 (15) 223 32 (16) 209 31 (7) 
Ischemic cardiomyopathy (n) 180 93 (52%) 194 99 (51%) 223 120 (54%) 209 119 (57%) 
MI > 3 months ago (n) 181 71 (39%) 194 69 (36%) 223 83 (37%) 209 98(47%) 
PCI > 3 months ago (n) 181 56 (31%) 194 74 (38%) 223 74 (33%) 209 98 (47%) 
CABG > 3 months ago (n) 181 35 (19%) 194 35 (18%) 223 39 (17%) 209 42 (20%) 
Hypertension (n) 178 119 (67%) 194 124 (64%) 223 151 (68% 205 137 (67%) 
Congenital heart disease (n) 175 3 (1.7%) 192 3 (1.6%) 220 7 (3.2%) 206 3 (1.5%) 
Prior ischemic stroke or TIA 
(n) 
180 28 (16%) 193 19 (10%) 221 19 (9%) 207 30 (14%) 
Diabetes (n) 181 69 (38%) 193 77 (40%) 222 84 (38%) 208 89 (43%) 
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Chronic lung disease (n) 180 33 (18%) 191 30 (16%) 220 45 (20%) 209 39 (19%) 
Chronic kidney disease (n) 180 17 (9%) 192 30 (16%) 220 25 (11%) 209 36 (17%) 
LV EF Biplane (%) 181 27.4 (5.3) 194 27.4 (5.5) 223 26.7 (5.6) 209 26.7 (5.8) 
LV end diastolic diameter 
(mm) 
181 66 (7) 194 67 (7) 223 67 (8) 209 67 (8) 
ACE inhibitor or ARB (n) 181 177 (98%) 194  185 (95%) 223 206 (92%) 209 197 (94%) 
Aldosterone antagonist (n) 181 105 (58%) 194  118 (61%) 223 132 (59%) 209  128 (61%) 
Beta-blocker (n) 181 178 (98%) 194 183 (94%) 223 216 (97%) 209 203 (97%) 
Diuretic agent (n) 181 160 (88%) 194 160 (82%) 223 191 (86%) 209 185 (88%) 
MR grade (n) 180  192  221  206  
  None/Trace  69 (38%)  64 (33%)  77 (35%)  69 (34%) 
  Mild  65 (36%)  80 (42%)  89 (40%)  83 (40%) 
  Moderate  25 (14%)  31 (16%)  34 (15%)  33 (16%) 
  Moderate/Severe  14 (8%)  11 (6%)  12 (5%)  14 (7%) 
  Severe  7 (4%)  6 (3%)  9 (4%)  7 (3%) 
LV ESV (ml) 180 134 (47) 194 140 (49) 223 142 (54) 207 142 (49) 
LV EDV (ml) 180 183 (57) 194 191 (58) 223 192 (65) 207 190 (55) 
TDI (ms) 181 97 (39) 194 98 (34) 223 105 (34) 208 104 (31) 
Speckle tracking (ms) 173 218 (109) 181 213 (100) 202 223 (102) 191 223 (99) 
AD= activation delay; NYHA= New York Heart Association; BNP= brain natriuretic peptide; SBP= 450 
systolic blood pressure; DBP= diastolic blood pressure; BMI= body mass index, MI= myocardial 451 
infarction; PCI= percutaneous coronary interventions; CABG= coronary artery bypass surgery; TIA= 452 
transient ischemic attack; LV= left ventricular; EF= ejection fraction; ACE= angiotensin converting 453 
enzyme; ARB= angiotensin II receptor blocker; MR= mitral regurgitation; EDV= end-diastolic volume; 454 
ESV= end-systolic volume; TDI= tissue Doppler imaging 455 





